Long-Term Remissions in Patients with Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Undergoing Allogeneic Transplantation Following a Reduced Intensity Conditioning Regimen of 550 cGy Total Body Irradiation and Cyclophosphamide
Christopher L. Hallemeier(Mayo Clinic in Arizona), Douglas R. Adkins(Washington University in St. Louis), Ravi Vij(Washington University in St. Louis), Mark D. Girgis, H.-S Lin(Washington University in St. Louis), H. Jean Khoury(Emory University), John F. DiPersio(Washington University in St. Louis), William Blum(The Ohio State University), Randy A. Brown(University of Florida), Steven M. Devine(National Marrow Donor Program)
Cited by 28
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k